Enveric Biosciences Canada Inc.

David James Press

Jillian M Hagel

Kaveh Matinkhoo

Peter James Facchini

Glynnis Elizabeth Jensen

Ye Cai

Jessica Bik-Jing Lee

Chang-Chun Ling

Disclosed are novel fused mescaline derivative compounds, notably substituted ethylamine fused heterocyclic mescaline derivatives, including substituted ethylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Substituted ethylamine fused heterocyclic mescaline derivatives

Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Fused heterocyclic mescaline derivatives

Disclosed are novel fused mescaline derivative compounds, notably substituted N-propylamine fused heterocyclic mescaline derivatives, including substituted N-propylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

Substituted n-propylamine fused heterocyclic mescaline derivatives

Disclosed are novel N-heterocycle-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.

N-heterocycle substituted tryptamine derivatives and methods of using

Disclosed are novel fused mescaline derivative compounds, notably C-substituted isopropylamine fused heterocyclic mescaline derivatives, including C-substituted isopropylamine fused dioxolane and fused dioxane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.

C1-substituted isopropylamine fused heterocyclic mescaline derivatives

Disclosed are novel C-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.

Growing community of inventors

Calgary, Canada

David James Press